Volume 7.11 | Mar 22

Pancreatic Cell News 7.11 March 22, 2016
Pancreatic Cell News
     In this issue: Publications | Reviews | Science News | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  PACN on Twitter
IBS Creates a Wearable Graphene-Based Biomedical Device to Monitor and Combat Diabetes
A scientific team has created a wearable graphene-based patch that allows accurate diabetes monitoring and feedback therapy by using human sweat. [Press release from the Institute for Basic Research discussing online prepublication in Nature Nanotechnology] Press Release | Abstract
Differentiation Doesn't Have to be Difficult - Get Easy, Standardized hPSC Differentiation
PUBLICATIONS (Ranked by impact factor of the journal)

Genetic Predisposition for Beta Cell Fragility Underlies Type 1 and Type 2 Diabetes
Investigators found a new genetic component of diabetes susceptibility in type 1 diabetes non-obese diabetic (NOD) mice, identifying immune-independent beta cell fragility. Genetic variation in Xrcc4 and Glis3 altered the response of NOD beta cells to unfolded protein stress, enhancing the apoptotic and senescent fates. [Nat Genet] Abstract | Press Release

Functional Identification of a Neurocircuit Regulating Blood Glucose
Scientists report that selective inhibition of the subset of hypothalamic ventromedial nucleus (VMN) neurons that express the transcription factor steroidogenic-factor 1 (VMNSF1 neurons) blocks recovery from insulin-induced hypoglycemia whereas, conversely, activation of VMNSF1 neurons causes diabetes-range hyperglycemia. [Proc Natl Acad Sci USA] Abstract

α/β-Hydrolase Domain 6 Deletion Induces Adipose Browning and Prevents Obesity and Type 2 Diabetes
The authors report that high-fat-diet-fed α/β-domain hydrolase-6-KO mice show modestly reduced food intake, decreased body weight gain and glycemia, improved glucose tolerance and insulin sensitivity, and enhanced locomotor activity. [Cell Rep] Full Article | Graphical Abstract

Rapid Elevation in CMPF May Act as a Tipping Point in Diabetes Development
To evaluate the effect of increasing CMPF on diabetes progression, researchers used obese, insulin-resistant models of prediabetes. CMPF accelerated diabetes development by inducing metabolic remodeling, resulting in preferential utilization of fatty acids over glucose. [Cell Rep] Full Article | Graphical Abstract

Glucagon-Like Peptide-1 Prevents Methylglyoxal-Induced Apoptosis of Beta Cells through Improving Mitochondrial Function and Suppressing Prolonged AMPK Activation
Researchers explored the signaling pathway involved in the anti-apoptotic effect of GLP-1, and investigated whether metformin had an anti-apoptotic effect on beta cells. [Sci Rep] Full Article

Ursodeoxycholic Acid and 4-Phenylbutyrate Prevent Endoplasmic Reticulum Stress-Induced Podocyte Apoptosis in Diabetic Nephropathy
The authors investigated the role of endoplasmic reticulum stress inhibitors ursodeoxycholic acid and 4-phenylbutyrate in the treatment of diabetic nephropathy in db/db mice. [Lab Invest] Abstract


Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma (PDAC)-Specific RNA Aptamers Inhibits Tumor Growth In Vivo
Scientists report a novel method for delivery of anti-tumorigenic therapy in PDAC by up-regulating the transcriptional factor CCAAT/enhancer-binding protein-a (C/EBPα), recognized for its antiproliferative effects. [Mol Ther] Full Article

Molecular Network, Pathway, and Functional Analysis of Time-Dependent Gene Changes Associated with Pancreatic Cancer Susceptibility to Oncolytic Vaccinia Virotherapy
Researchers determined changes in gene expression patterns associated with infection and susceptibility of pancreatic cancer cells to an oncolyticvaccinia virus, GLV-1h153, carrying the human sodium iodide symporter for deep tissue imaging of virotherapy. [Mol Ther Oncolytics] Full Article

Learn More: Standardized Tools for Cancer Research
Pursuit of a Perfect Insulin
The development of an insulin therapy that is responsive to glucose concentration remains an ultimate goal, with initial prototypes now reaching the proof-of-concept stage. Simultaneously, the first alternatives to injectable delivery have progressed to registration. [Nat Rev Drug Discov] Abstract

Assessment of Bone Turnover and Bone Quality in Type 2 Diabetic Bone Disease: Current Concepts and Future Directions
Bone imaging technologies, including trabecular bone score and quantitative CT testing have revealed differences in diabetic bone as compared to non-diabetic individuals. Specifically, high resolution peripheral quantitative CT imaging has demonstrated increased cortical porosity in diabetic postmenopausal women. [Bone Res] Full Article

Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.
ARMO BioSciences to Present New Clinical Trial Results for AM0010 at Upcoming Medical Conferences
ARMO BioSciences, Inc. announced that positive results from an ongoing Phase I clinical trial of ARMO’s investigational drug AM0010 for the treatment of advanced solid tumors will be presented as oral presentations at two upcoming oncology medical meetings. [Press release from ARMO BioSciences, Inc. (PR Newswire Association LLC.) discussing research to be presented at the 3rd Immunotherapy of Cancer Conference (ITOC3), Munich and AACR Annual Meeting 2016, New Orleans] Press Release

Real-World Data on XARELTO® in Patients with Non-Valvular Atrial Fibrillation and Diabetes Among 13 Presentations at American College of Cardiology’s 65th Annual Scientific Session
Janssen Pharmaceuticals Inc. and Bayer announced that 13 data presentations will be presented including real-world findings confirming the safety of XARELTO® (rivaroxaban) in a high-risk group of patients with non-valvular atrial fibrillation and concomitant diabetes. [Press release from Janssen Pharmaceuticals, Inc. discussing research to be presented at the American College of Cardiology’s 65th Annual Scientific Session (ACC.16), Chicago] Press Release

From our sponsor:
Pluripotent cell isolation for regenerative medicine.
Request a free wallchart from Nature.
Halozyme Doses First Patient in Phase III Clinical Trial Of PEGPH20 In Combination With ABRAXANE® And Gemcitabine
Halozyme Therapeutics, Inc. announced the first patient has been dosed in its Halo-301 | Pancreatic study, a Phase III clinical trial in previously untreated metastatic pancreatic cancer patients. [Halozyme Therapeutics, Inc.] Press Release

Targovax Announces Encouraging Interim Results with Ras Specific Pepetide Vaccine in Resected Pancreatic Cancer
Targovax has conducted a predetermined interim analysis of the TG01 Phase I/II trial, indicating promising one year overall survival data when combining TG01 with gemcitabine (chemotherapy) as supplementary treatment of patients with pancreatic cancer. [Targovax] Press Release

MabVax Therapeutics Initiates Phase I Trial of HuMab-5B1 for Treatment of Pancreatic Cancer
MabVax Therapeutics Holdings, Inc. announced initiation of a Phase I clinical trial of HuMab-5B1 for patients with locally advanced or metastatic adenocarcinoma of the pancreas or other CA19-9 positive malignancies. [MabVax Therapeutics Holdings, Inc.] Press Release
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW Summit for Cancer Immunotherapy
June 26-29, 2016
Halifax, Canada

Visit our events page to see a complete list of events in the pancreatic cell community.
NEW Research Scientist – Various Fields (King Abdullah International Medical Research Center)

Postdoctoral Fellowship – Pancreatic Cancer (Fred Hutchinson Cancer Research Center)

Master Studentship – Exercise and Diabetes (Swansea University)

Part Time Researcher – Diabetes (University of Bergen)

Postdoctoral Research Fellowship – Pancreatic Cancer Biology (Fred Hutchinson Cancer Research Center)

Postdoctoral Research Fellowship – Surgical Oncology in Pancreatic Cancer (University of Nebraska Medical Center)

Postdoctoral Research Fellowship – Pancreatic Progenitors in Development (Johns Hopkins University Institute of Genetic Medicine)

Postdoctoral Fellowship – Metabolism and Cancer (Monash University)

Postdoctoral Fellowship – Mechanisms of Atherosclerosis, Diabetes and Obesity (Washington University School of Medicine)

Assistant Professor of Surgery – Molecular Biology and Pancreatic Development (University of Pittsburgh)

Postdoctoral Fellowship – Neural Mechanisms of Diabetes (Albert Einstein College of Medicine)

Faculty Position – Metabolic Disease Research (Lewis Katz School of Medicine)

Post-Doc Fellowship – Glucose Metabolism (Joslin Diabetes Center)

MD/PhD Researcher – Biomedical Sciences (Hannover Medical School)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Pancreatic Cell News: Archives | Events | Contact Us